文献速递妇产影像儿科影像神经US

用于衔接产前与新生儿脑生长评估的新型超声测量指标

New Ultrasound Measurements to Bridge the Gap between Prenatal and Neonatal Brain Growth Assessment.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-06-29

本研究基于前瞻性鹿特丹围孕期队列,在22、26、32周对胎儿行3D超声、生后42周行颅脑超声,测量胼胝体长度与胼胝体-顶长度。两种测量信度优秀(组内相关系数≥0.97);与对照组相比,胎儿生长受限和先天性心脏病组的胼胝体生长轨迹显著降低,胎儿生长受限组的胼胝体-顶生长轨迹降低。作者认为这两种长度可能作为从产前到生后监测脑生长的可靠指标。

要点

  • 胼胝体长度与胼胝体-顶长度产前3D超声与生后颅脑超声均可测量,信度优秀(组内相关系数≥0.97)。
  • 与对照组相比,胎儿生长受限和先天性心脏病组的胼胝体生长轨迹显著降低。
  • 胎儿生长受限组的胼胝体-顶生长轨迹较对照组降低(β=-1.295;95%CI -2.595-0.003;P=.05)。

核心结论

  • 胼胝体长度和胼胝体-顶长度可能作为从产前到生后监测脑生长的可靠指标,其临床适用性由高危胎儿与对照之间显著不同的生长轨迹所支持。

研究设计与样本

  • 嵌入前瞻性鹿特丹围孕期队列的3D超声研究,纳入199例胎儿(胎儿生长受限22例、先天性心脏病20例、对照157例),于22、26、32周行产前3D超声,生后42周行颅脑超声。

诊断标准与关键数值

  • 胼胝体长度与胼胝体-顶长度测量信度优秀,组内相关系数≥0.97。
  • 与对照组相比,胎儿生长受限组胼胝体生长轨迹降低(β=-2.295;95%CI -3.320至-1.270;P<.01)。
  • 与对照组相比,先天性心脏病组胼胝体生长轨迹降低(β=-1.267;95%CI -0.972至0.562;P<.01)。
  • 与对照组相比,胎儿生长受限组胼胝体-顶生长轨迹降低(β=-1.295;95%CI -2.595至0.003;P=.05)。

临床应用与阅片要点

  • 产前3D超声与生后颅脑超声均可测量胼胝体长度和胼胝体-顶长度,可用于衔接产前与生后脑生长监测。
  • 对胎儿生长受限和先天性心脏病胎儿,可参考胼胝体及胼胝体-顶长度生长轨迹与对照的差异进行随访评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Most ultrasound markers for monitoring brain growth can only be used in either the prenatal or the postnatal period. We investigated whether corpus callosum length and corpus callosum-fastigium length could be used as markers for both prenatal and postnatal brain growth.

MATERIALS AND METHODS: A 3D ultrasound study embedded in the prospective Rotterdam Periconception Cohort was performed at 22, 26 and 32 weeks' gestational age in fetuses with fetal growth restriction, congenital heart defects, and controls. Postnatally, cranial ultrasound was performed at 42 weeks' postmenstrual age. First, reliability was evaluated. Second, associations between prenatal and postnatal corpus callosum and corpus callosum-fastigium length were investigated. Third, we created reference curves and compared corpus callosum and corpus callosum-fastigium length growth trajectories of controls with growth trajectories of fetuses with fetal growth retardation and congenital heart defects.

RESULTS: We included 199 fetuses; 22 with fetal growth retardation, 20 with congenital heart defects, and 157 controls. Reliability of both measurements was excellent (intraclass correlation coefficient ≥ 0.97). Corpus callosum growth trajectories were significantly decreased in fetuses with fetal growth restriction and congenital heart defects (β = -2.295; 95% CI, -3.320-1.270; P < .01; β = -1.267; 95% CI, -0.972-0.562; P < .01, respectively) compared with growth trajectories of controls. Corpus callosum-fastigium growth trajectories were decreased in fetuses with fetal growth restriction (β = -1.295; 95% CI, -2.595-0.003; P = .05).

CONCLUSIONS: Corpus callosum and corpus callosum-fastigium length may serve as reliable markers for monitoring brain growth from the prenatal into the postnatal period. The clinical applicability of these markers was established by the significantly different corpus callosum and corpus callosum-fastigium growth trajectories in fetuses at risk for abnormal brain growth compared with those of controls.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Koning IV, Roelants JA, Groenenberg IAL, et al. New Ultrasound Measurements to Bridge the Gap between Prenatal and Neonatal Brain Growth Assessment. AJNR Am J Neuroradiol. 2017. PMID: 28663264. doi:10.3174/ajnr.A5278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。